Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1

References

• BrissosSVeguillaMRTaylorDBalanzá-MartinezVThe role of long-acting injectable antipsychotics in schizophrenia: a critical appraisalTher Adv Psychopharmacol20144519821925360245
   PubMedGoogle Scholar
• KaplanGCasoyJZummoJImpact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophreniaPatient Prefer Adherence201371171118024265549
   PubMed Web of Science ®Google Scholar
• OffordSWongBMirskiDBakerRALinJHealthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oralJ Med Econ201316223123923163287
   PubMedGoogle Scholar
• CorrellCUCitromeLHaddadPMThe use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidenceJ Clin Psychiatry201677Suppl 312427732772
   PubMed Web of Science ®Google Scholar
• GiganteADLaferBYathamLNLong-acting injectable antipsychotics for the maintenance treatment of bipolar disorderCNS Drugs201226540342022494448
   PubMed Web of Science ®Google Scholar
• NasrallahHAThe case for long-acting antipsychotic agents in the post-CATIE eraActa Psychiatr Scand2007115426026717355516
   PubMed Web of Science ®Google Scholar
• OlivaresJMRodriguez-MoralesADielsJe-STAR Spanish Study GroupLong-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR)Eur Psychiatry200924528729619195847
   PubMed Web of Science ®Google Scholar
• HaddadPMKishimotoTCorrellCUKaneJMAmbiguous findings concerning potential advantages of depot antipsychotics: in search of clinical relevanceCurr Opin Psychiatry201528321622125785710
   PubMed Web of Science ®Google Scholar
• KishimotoTRobenzadehALeuchtCLong-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trialsSchizophr Bull201440119221323256986
   PubMed Web of Science ®Google Scholar
• AlphsLMaoLLynn StarrHBensonCA pragmatic analysis comparing once-monthly paliperidone palmitate versus daily oral antipsychotic treatment in patients with schizophreniaSchizophr Res20161702–325926426742509
   PubMed Web of Science ®Google Scholar
• SchreinerAAadamsooKAltamuraACPaliperidone palmitate versus oral antipsychotics in recently diagnosed schizophreniaSchizophr Res20151691–339339926431793
   PubMed Web of Science ®Google Scholar
• SubotnikKLCasausLRVenturaJLong-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trialJAMA Psychiatry201572882282926107752
   PubMed Web of Science ®Google Scholar
• KishimotoTNittaMBorensteinMKaneJMCorrellCULong-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studiesJ Clin Psychiatry2013741095796524229745
   PubMed Web of Science ®Google Scholar
• KishimotoTHagiKNittaMEffectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studiesSchizophr Bull2017443603619
   Web of Science ®Google Scholar
• KaneJMKishimotoTCorrellCUAssessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatryJ Clin Epidemiol2013668 SupplS37S4123849151
   PubMed Web of Science ®Google Scholar
• LlorcaPMAbbarMCourtetPGuillaumeSLancrenonSSamalinLGuidelines for the use and management of long-acting injectable antipsychotics in serious mental illnessBMC Psychiatry20131334024359031
   PubMed Web of Science ®Google Scholar
• LehmanAFLiebermanJADixonLBAmerican Psychiatric Association; Steering Committee on Practice GuidelinesPractice guideline for the treatment of patients with schizophrenia, second editionAm J Psychiatry20041612 Suppl156
   PubMed Web of Science ®Google Scholar
• ChouYHChuPCWuSWA systemic review and experts’ consensus for long-acting injectable antipsychotics in bipolar disorderClin Psychopharmacol Neurosci201513212112826243837
   PubMed Web of Science ®Google Scholar
• YathamLNKennedySHParikhSVCanadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013Bipolar Disord201315114423237061
   PubMed Web of Science ®Google Scholar
• KaneJMKishimotoTCorrellCUNon-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategiesWorld Psychiatry201312321622624096780
   PubMed Web of Science ®Google Scholar
• LacroJPDunnLBDolderCRLeckbandSGJesteDVPrevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literatureJ Clin Psychiatry2002631089290912416599
   PubMed Web of Science ®Google Scholar
• CarbonMCorrellCUClinical predictors of therapeutic response to antipsychotics in schizophreniaDialogues Clin Neurosci201416450552425733955
   PubMed Web of Science ®Google Scholar
• GarciaSMartinez-CengotitabengoaMLopez-ZurbanoSAdherence to antipsychotic medication in bipolar disorder and schizophrenic patients: a systematic reviewJ Clin Psychopharmacol201636435537127307187
   PubMed Web of Science ®Google Scholar
• PatelMXHaddadPMChaudhryIBMcLoughlinSHusainNDavidASPsychiatrists’ use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 yearsJ Psychopharmacol201024101473148219477883
   PubMed Web of Science ®Google Scholar
• ByerlyMJThompsonACarmodyTValidity of electronically monitored medication adherence and conventional adherence measures in schizophreniaPsychiatr Serv200758684484717535946
   PubMed Web of Science ®Google Scholar
• StephensonJJTunceliOGuTAdherence to oral second-generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians’ perceptions of adherence vs. pharmacy claimsInt J Clin Pract201266656557322574724
   PubMed Web of Science ®Google Scholar
• BarnesTRShingleton-SmithAPatonCAntipsychotic long-acting injections: prescribing practice in the UKBr J Psychiatry Suppl200952S37S4219880915
   PubMedGoogle Scholar
• RauchASFleischhackerWWLong-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspectiveCNS Drugs201327863765223780619
   PubMed Web of Science ®Google Scholar
• WeidenPJRomaRSVelliganDIAlphsLDiChiaraMDavidsonBThe challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophreniaJ Clin Psychiatry201576668469025939027
   PubMed Web of Science ®Google Scholar
• SajatovicMDiBiasiFLegacySNAttitudes toward antipsychotic treatment among patients with bipolar disorders and their clinicians: a systematic reviewNeuropsychiatr Dis Treat2017132285229628919760
   PubMed Web of Science ®Google Scholar
• KahnDADochertyJPCarpenterDFrancesAConsensus methods in practice guideline development: a review and description of a new methodPsychopharmacol Bull19973346316399493472
   PubMedGoogle Scholar
• BrookRHChassinMRFinkASolomonDHKosecoffJParkREA method for the detailed assessment of the appropriateness of medical technologiesInt J Technol Assess Health Care198621536310300718
   PubMedGoogle Scholar
• WeidenPJPreskornSHFahnestockPACarpenterDRossRDochertyJPRoadmap SurveyTranslating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness: a roadmapJ Clin Psychiatry200768Suppl 714817650057
   PubMed Web of Science ®Google Scholar
• LeclercEMansurRBBrietzkeEDeterminants of adherence to treatment in bipolar disorder: a comprehensive reviewJ Affect Disord20131491–324725223489403
   PubMed Web of Science ®Google Scholar
• ParelladaEBioqueMBarriers to the use of long-acting injectable antipsychotics in the management of schizophreniaCNS Drugs201630868970127255405
   PubMed Web of Science ®Google Scholar
• KaneJMGarcia-RiberaCClinical guideline recommendations for antipsychotic long-acting injectionsBr J Psychiatry Suppl200952S63S6719880920
   PubMedGoogle Scholar
• JaremaMWichniakADudekDSamochowiecJBieńkowskiPRybakowskiJGuidelines for the use of second-generation long-acting antipsychoticsPsychiatr Pol2015492225241 Polish [with English abstract]26093588
   PubMed Web of Science ®Google Scholar
• GeertsPMartinezGSchreinerAAttitudes towards the administration of long-acting antipsychotics: a survey of physicians and nursesBMC Psychiatry2013135823414331
   PubMed Web of Science ®Google Scholar
• HeresSHamannJKisslingWLeuchtSAttitudes of psychiatrists toward antipsychotic depot medicationJ Clin Psychiatry200667121948195317194274
   PubMed Web of Science ®Google Scholar
• JaegerMRosslerWAttitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatristsPsychiatry Res20101751–2586220004980
   PubMed Web of Science ®Google Scholar
• De RisioALangAPHistory and therapeutic rationale of long acting antipsychoticsCurr Clin Pharmacol201491395223343446
   PubMedGoogle Scholar
• BartzokisGLuPHAmarCPLong acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectorySchizophr Res20111321354121767934
   PubMed Web of Science ®Google Scholar
• BartzokisGLuPHRavenEPImpact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophreniaSchizophr Res20121401–312212822809684
   PubMed Web of Science ®Google Scholar
• KaneJMLeuchtSCarpenterDDochertyJPExpert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic DisordersThe expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summaryJ Clin Psychiatry200364Suppl 12519
   PubMed Web of Science ®Google Scholar
• McEvoyJPScheiflerPLFrancesAThe expert consensus guidelines series: treatment of schizophreniaJ Clin Psychiatry199960Suppl 11180
   Google Scholar
• KeckPEPerlisRHOttoMWCarpenterDDochertyJPRossRThe expert consensus guideline series: treatment of bipolar disorder 2004Postgraduate Medicine Special Report20041116
   Google Scholar
• SajatovicMRossRLegacySNInitiating/maintaining long-acting injectable antipsychotics in schizophrenia/schizoaffective or bipolar disorder–expert consensus survey part 2Neuropsychiatr Dis Treat2018
   Web of Science ®Google Scholar